Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Социальные и психологические факторы риска снижения приверженности терапии у пациентов с фибрилляцией предсердий
Трошина Д.В., Андреев Д.А., Фомичева А.В., Воловченко А.Н., Волель Б.А. Социальные и психологические факторы риска снижения приверженности терапии у пациентов с фибрилляцией предсердий. Терапевтический архив. 2022;94(10):1197–1203. DOI: 10.26442/00403660.2022.10.201905
© ООО «КОНСИЛИУМ МЕДИКУМ», 2022 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2022 г.
________________________________________________
Troshina DV, Andreev DA, Fomicheva AV, Volovchenko AN, Volel BA. Social and psychological risk factors for decreased adherence among patients with atrial fibrillation. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(10):1197–1203. DOI: 10.26442/00403660.2022.10.201905
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Неприверженность терапии снижает эффективность терапии фибрилляции предсердий и повышает риск развития тромбоэмболических осложнений. Среди факторов, соучаствующих в ухудшении приверженности терапии, социальные и психологические характеристики пациентов по-прежнему остаются недостаточно изученными. В то же время доступные публикации позволяют сделать вывод о наличии маркеров уязвимости в отношении риска снижения приверженности терапии больных с фибрилляцией предсердий, к которым относятся пожилой возраст, когнитивные нарушения, психоэмоциональные расстройства (в том числе депрессия и тревога) и специфические поведенческие паттерны.
Ключевые слова: фибрилляция предсердий, приверженность терапии, социально-демографические факторы, когнитивные нарушения, депрессия, тревога, личность
Ключевые слова: фибрилляция предсердий, приверженность терапии, социально-демографические факторы, когнитивные нарушения, депрессия, тревога, личность
________________________________________________
Adherence has a direct impact on reducing the effectiveness of atrial fibrillation therapy and increasing the risk of thromboembolic events. Among the factors involved in the decrease of adherence, the social and psychological characteristics of patients remain insufficiently studied. At the same time, the available publications allow us to conclude that there are markers of the risk of reduced adherence in patients with atrial fibrillation, which include age, cognitive impairment, psychoemotional disorders (including depression and anxiety) and specific behavioral patterns.
Keywords: atrial fibrillation, adherence, socio-demographic factors, cognitive impairment, depression, anxiety, personality
Полный текст
Список литературы
1. Chugh S, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47. DOI:10.1161/CIRCULATIONAHA.113.005119
2. Dai H, Zhang Q, Much A, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):574-82. DOI:10.1093/ehjqcco/qcaa061
3. Мареев Ю.В., Поляков Д.С., Виноградова Н.Г., и др. ЭПОХА: Эпидемиология фибрилляции предсердий в репрезентативной выборке Европейской части Российской Федерации. Кардиология. 2022;62(4):12-9 [Mareev YuV, Polyakov DS, Vinogradova NG, et al. Epidemiology of atrial fibrillation in a representative sample of the European part of the Russian Federation. Analysis of EPOCH-CHF Study. Kardiologiia. 2022;62(4):12-9 (in Russian)]. DOI:10.18087/cardio.2022.4.n1997
4. Беленков Ю.Н., Шакарьянц Г.А., Хабарова Н.В., Ан Г.В. Антикоагулянтная терапия у пожилых пациентов с фибрилляцией предсердий. Кардиология. 2018;58(10):45-52 [Belenkov YuN, Shakaryants GA, Khabarova NV, An GV. Anticoagulant Therapy in Elderly Patients With Atrial Fibrillation. Kardiologiia. 2018;58(10):45-52 (in Russian)]. DOI:10.18087/cardio.2018.10.10177
5. Бокерия Л.А., Полунина А.Г., Лефтерова Н.П., и др. Фибрилляция предсердий, дилатация левых камер сердца: пусковые механизмы развития когнитивных нарушений у кардиологических пациентов. Креативная кардиология. 2015;9(1):38-45 [Bockeria LA, Polunina AG, Lefterova NF, et al. Atrium fibrillation and enlargement of left heart chambers: pathological mechanisms of cognitive dysfunction in cardiologic patients. Creative Cardiology. 2015;9(1):38-45 (in Russian)]. DOI:10.15275/kreatkard.2015.01.04
6. Диагностика и лечение фибрилляции предсердий. Клинические рекомендации, 2017. Режим доступа: https://racvs.ru/clinic/files/2017/Atrial-Fibrillation.pdf. Ссылка активна на 26.09.2022 [Diagnostika i lechenie fibrilliatsii predserdii. Klinicheskie rekomendatsii, 2017. Available at: https://racvs.ru/clinic/files/2017/Atrial-Fibrillation.pdf. Accessed: 26.09.2022 (in Russian)].
7. Salmasi S, Loewen P, Tandun R, et al. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. BMJ Open. 2020;10(4):e034778. DOI:10.1136/bmjopen-2019-034778
8. Jankowska-Polańska B, Lomper K, Alberska L, et al. Cognitive function and adherence to anticoagulation treatment in patients with atrial fibrillation. J Geriatr Cardiol. 2016;13(7):559. DOI:10.11909/j.issn.1671-5411.2016.07.006
9. Obamiro K, Chalmers L, Lee K, et al. Adherence to oral anticoagulants in atrial fibrillation: An Australian survey. Cardiovasc Pharm Ther. 2018;23:337-43. DOI:10.1177/1074248418770201
10. Seong H, Lee K, Kim B, Son Y. Cognitive impairment is independently associated with non-adherence to antithrombotic therapy in older patients with atrial fibrillation. Int J Environ Res Public Health. 2019;16(15):2698. DOI:10.3390/ijerph16152698
11. Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Thromb Haemost. 2017;117(02):209-18.
DOI:10.1160/TH16-10-0757
12. Cramer J, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7. DOI:10.1111/j.1524-4733.2007.00213.x
13. Tomasdottir M, Friberg L, Hijazi Z, et al. Risk of ischemic stroke and utility of CHA2DS2-VASc score in women and men with atrial fibrillation. Clin Cardiol. 2019;42(10):1003-9. DOI:10.1002/clc.23257
14. Lip G, Laroche C, Popescu M, et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. EP Europace. 2015;17(12):1777-86. DOI:10.1093/europace/euv269
15. Thompson L, Maddox T, Lei L, et al. Sex differences in the use of oral anticoagulants for atrial fibrillation: a report from the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry. J Am Heart Assoc. 2017;6(7):e005801. DOI:10.1161/JAHA.117.005801
16. Eckman M, Wise R, Leonard A, et al. Racial and sex differences in optimizing anticoagulation therapy for patients with atrial fibrillation. American Heart Journal Plus: Cardiology Research and Practice. 2022;18:100170. DOI:10.1016/j.ahjo.2022.100170
17. Charlton A, Vidal X, Sabaté M, et al. Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation. J Manag Care Specy Pharm. 2021;27(9):1210-20. DOI:10.18553/jmcp.2021.27.9.1210
18. Bartolazzi F, Ribeiro A, de Sousa W, et al. Relationship of health literacy and adherence to oral anticoagulation therapy in patients with atrial fibrillation: a cross-sectional study. J Thromb Thrombolysis. 2021;52(4):1074-80. DOI:10.1007/s11239-021-02432-4
19. Ferguson C, Inglis S, Newton P, et al. Barriers and enablers to adherence to anticoagulation in heart failure with atrial fibrillation: patient and provider perspectives. J Clin Nurs. 2017;26(23-24):4325-34. DOI:10.1111/jocn.13759
20. Cabellos-Garcia A, Martinez-Sabater A, Castro-Sanchez E, et al. Relation between health literacy, self-care and adherence to treatment with oral anticoagulants in adults: a narrative systematic review. BMC Public Health. 2018;18(1):1-12. DOI:10.1186/s12889-018-6070-9
21. Lemstra M, Nwankwo C, Bird Y, Moraros J. Primary nonadherence to chronic disease medications: a meta-analysis. Patient Prefer Adherence. 2018;12:721. DOI:10.2147/PPA.S161151
22. Mandalenakis Z, Von Koch L, Eriksson H, et al. The risk of atrial fibrillation in the general male population: a lifetime follow-up of 50-year-old men. Europace. 2015;17(7):1018-22. DOI:10.1093/europace/euv036
23. Friberg L, Rosenqvist M, Lip G. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-10. DOI:10.1093/eurheartj/ehr488
24. LaMori J, Mody S, Gross H, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53-62. DOI:10.1177/17539447124641
25. Деменко Т.Н., Чумакова Г.А., Чугунова Ю.В. Особенности когнитивной функции у пациентов с фибрилляцией предсердий. Анналы аритмологии. 2015;12(4):215-24 [Demenko TN, Chumakova GA, Chugunova YV. Features of cognitive function in patients with atrial fibrillation. Annaly aritmologii. 2015;12(4):215-24 (in Russian)]. DOI:10.15275/annaritmol.2015.4.3
26. Rohde D, Merriman N, Doyle F, et al. Does cognitive impairment impact adherence? A systematic review and meta-analysis of the association between cognitive impairment and medication non-adherence in stroke. PloS One. 2017;12(12):e0189339. DOI:10.1371/journal.pone.0189339
27. Кобалава Ж.Д., Лазарев П.В., Федорова Д.Н. Когнитивная дисфункция на фоне фибрилляции предсердий: клинико-патогенетические ассоциации, диагностика и профилактика, аспекты применения антикоагулянтной терапии. Кардиология. 2019;59(10):66-77 [Kobalava ZD, Lazarev PV, Fedorova DN. Cognitive Dysfunction at the Background of Atrial Fibrillation: Clinical-Pathological Aspects, Diagnostics and Prevention, Issues of the Use of the Application of Anticoagulant Therapy. Kardiologiia. 2019;59(10):66-77 (in Russian)]. DOI:10.18087/cardio.2019.10.n612
28. Gallagher A, Rietbrock S, Plumb J, Van Staa T. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemostas. 2008;6(9):1500-6. DOI:10.1111/j.1538-7836.2008.03059.x
29. Castellucci L, Shaw J, van der Salm K, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thrombosis Res. 2015;136(4):727-31. DOI:10.1016/j.thromres.2015.07.007
30. Emren S, Şenöz O, Bilgin M, et al. Drug adherence in patients with nonvalvular atrial fibrillation taking non-vitamin K antagonist oral anticoagulants in Turkey: NOAC-TR. Clin Appl Thromb Hemost. 2018;24(3):525-31. DOI:10.1177/1076029617693940
31. Zielinski G, van Rein N, Teichert M, et al. Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: a surveillance study. Res Pract Thromb Haemost. 2020;4(1):141-53. DOI:10.1002/rth2.12261
32. Smith D, Lovell J, Weller C, et al. A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PloS One. 2017;12(2):e0170651. DOI:10.1371/journal.pone.0170651
33. Patel D, McConkey N, Sohaney R, et al. A systematic review of depression and anxiety in patients with atrial fibrillation: the mind-heart link. Cardiovasc Psychiatry Neurol. 2013;2013:159850. DOI:10.1155/2013/159850
34. Polikandrioti M, Koutelekos I, Vasilopoulos G, et al. Anxiety and depression in patients with permanent atrial fibrillation: prevalence and associated factors. Cardiol Res Pract. 2018;2018:7408129. DOI:10.1155/2018/7408129
35. Søgaard M, Skjøth F, Kjældgaard J, et al. Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study. BMJ Open. 2017;7(12):e018209. DOI:10.1136/bmjopen-2017-018209
36. Wu M, Shen L, Wang Q, et al. Anxiety and Depression Prevalence and Risk Factors Among Patients With Cardiovascular Diseases in Post-COVID-19 China. Front Public Health. 2022;9:758874. DOI:10.3389/fpubh.2021.758874
37. Walker E, McGee R, Druss B. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334-41. DOI:10.1001/jamapsychiatry.2014.2502
38. Jayatilleke N, Hayes R, Dutta R, et al. Contributions of specific causes of death to lost life expectancy in severe mental illness. Eur Psychiatry. 2017;43:109-15. DOI:10.1016/j.eurpsy.2017.02.487
39. McGrady A, McGinnis R, Badenhop D, et al. Effects of depression and anxiety on adherence to cardiac rehabilitation. J Cardiopulm Rehabil Prevn. 2009;29(6):358-64. DOI:10.1097/HCR.0b013e3181be7a8f
40. Fenger-Grøn M, Vestergaard C, Frost L, et al. Depression and uptake of oral anticoagulation therapy in patients with atrial fibrillation: a Danish nationwide cohort study. Medical Care. 2020;58(3):216-24. DOI:10.1097/MLR.0000000000001268
41. Reading S, Black M, Singer D, et al. Risk factors for medication non-adherence among atrial fibrillation patients. BMC Cardiovasc Disord. 2019;19(1):38.
DOI:10.1186/s12872-019-1019-1
42. Bauer LK, Caro MA, Beach SR, et al. Effects of depression and anxiety improvement on adherence to medication and health behaviors in recently hospitalized cardiac patients. Am J Cardiol. 2012;109(9):1266-71. DOI:10.1016/j.amjcard.2011.12.017
43. Suzuki T, Shiga T, Omori H, et al. Adherence to medication and characteristics of Japanese patients with non-valvular atrial fibrillation. J Cardiol. 2017;70(3):238-43. DOI:10.1016/j.jjcc.2016.11.009
44. Taylor E, O'Neill M, Hughes L, et al. Examining adherence to medication in patients with atrial fibrillation: the role of medication beliefs, attitudes, and depression. J Cardiovasc Nurs. 2020;35(4):337-46. DOI:10.1097/JCN.0000000000000650
45. Teppo K, Jaakkola J, Airaksinen K, et al. Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study. J Am Heart Assoc. 2022;11(6):e024119. DOI:10.1161/JAHA.121.024119
46. Miyazaki M, Nakashima A, Nakamura Y, et al. Association between medication adherence and illness perceptions in atrial fibrillation patients treated with direct oral anticoagulants: an observational cross-sectional pilot study. PloS One. 2018;13(9):e0204814. DOI:10.1371/journal.pone.0204814
47. Lane D, Meyerhoff J, Rohner U, Lip G. Patients’ perceptions of atrial fibrillation, stroke risk, and oral anticoagulation treatment: An international survey. TH Open. 2018;2(03):e233-41. DOI:10.1055/s-0038-1666803
48. Алёхин А.Н., Трифонова Е.А., Лебедев Д.С., и др. Психологические проблемы в аритмологии (на модели фибрилляции предсердий). Вестник аритмологии. 2011;63:45-54 [Alekhin AN, Trifonova EA, Lebedev DS, et al. Psuchological problems in arrhythmology (on a model of atrial fibrillation). Vestnik aritmologii. 2011;63:45-54 (in Russian)].
49. Streur M, Ratcliffe SJ, Callans D, et al. Atrial fibrillation symptom clusters and associated clinical characteristics and outcomes: A cross-sectional secondary data analysis. Eur J Cardiovasc Nurs. 2018;17(8):707-16. DOI:10.1177/1474515118778445
2. Dai H, Zhang Q, Much A, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):574-82. DOI:10.1093/ehjqcco/qcaa061
3. Мареев Ю.В., Поляков Д.С., Виноградова Н.Г., и др. ЭПОХА: Эпидемиология фибрилляции предсердий в репрезентативной выборке Европейской части Российской Федерации. Кардиология. 2022;62(4):12-9 [Mareev YuV, Polyakov DS, Vinogradova NG, et al. Epidemiology of atrial fibrillation in a representative sample of the European part of the Russian Federation. Analysis of EPOCH-CHF Study. Kardiologiia. 2022;62(4):12-9 (in Russian)]. DOI:10.18087/cardio.2022.4.n1997
4. Беленков Ю.Н., Шакарьянц Г.А., Хабарова Н.В., Ан Г.В. Антикоагулянтная терапия у пожилых пациентов с фибрилляцией предсердий. Кардиология. 2018;58(10):45-52 [Belenkov YuN, Shakaryants GA, Khabarova NV, An GV. Anticoagulant Therapy in Elderly Patients With Atrial Fibrillation. Kardiologiia. 2018;58(10):45-52 (in Russian)]. DOI:10.18087/cardio.2018.10.10177
5. Бокерия Л.А., Полунина А.Г., Лефтерова Н.П., и др. Фибрилляция предсердий, дилатация левых камер сердца: пусковые механизмы развития когнитивных нарушений у кардиологических пациентов. Креативная кардиология. 2015;9(1):38-45 [Bockeria LA, Polunina AG, Lefterova NF, et al. Atrium fibrillation and enlargement of left heart chambers: pathological mechanisms of cognitive dysfunction in cardiologic patients. Creative Cardiology. 2015;9(1):38-45 (in Russian)]. DOI:10.15275/kreatkard.2015.01.04
6. Диагностика и лечение фибрилляции предсердий. Клинические рекомендации, 2017. Режим доступа: https://racvs.ru/clinic/files/2017/Atrial-Fibrillation.pdf. Ссылка активна на 26.09.2022 [Diagnostika i lechenie fibrilliatsii predserdii. Klinicheskie rekomendatsii, 2017. Available at: https://racvs.ru/clinic/files/2017/Atrial-Fibrillation.pdf. Accessed: 26.09.2022 (in Russian)].
7. Salmasi S, Loewen P, Tandun R, et al. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. BMJ Open. 2020;10(4):e034778. DOI:10.1136/bmjopen-2019-034778
8. Jankowska-Polańska B, Lomper K, Alberska L, et al. Cognitive function and adherence to anticoagulation treatment in patients with atrial fibrillation. J Geriatr Cardiol. 2016;13(7):559. DOI:10.11909/j.issn.1671-5411.2016.07.006
9. Obamiro K, Chalmers L, Lee K, et al. Adherence to oral anticoagulants in atrial fibrillation: An Australian survey. Cardiovasc Pharm Ther. 2018;23:337-43. DOI:10.1177/1074248418770201
10. Seong H, Lee K, Kim B, Son Y. Cognitive impairment is independently associated with non-adherence to antithrombotic therapy in older patients with atrial fibrillation. Int J Environ Res Public Health. 2019;16(15):2698. DOI:10.3390/ijerph16152698
11. Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Thromb Haemost. 2017;117(02):209-18.
DOI:10.1160/TH16-10-0757
12. Cramer J, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7. DOI:10.1111/j.1524-4733.2007.00213.x
13. Tomasdottir M, Friberg L, Hijazi Z, et al. Risk of ischemic stroke and utility of CHA2DS2-VASc score in women and men with atrial fibrillation. Clin Cardiol. 2019;42(10):1003-9. DOI:10.1002/clc.23257
14. Lip G, Laroche C, Popescu M, et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. EP Europace. 2015;17(12):1777-86. DOI:10.1093/europace/euv269
15. Thompson L, Maddox T, Lei L, et al. Sex differences in the use of oral anticoagulants for atrial fibrillation: a report from the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry. J Am Heart Assoc. 2017;6(7):e005801. DOI:10.1161/JAHA.117.005801
16. Eckman M, Wise R, Leonard A, et al. Racial and sex differences in optimizing anticoagulation therapy for patients with atrial fibrillation. American Heart Journal Plus: Cardiology Research and Practice. 2022;18:100170. DOI:10.1016/j.ahjo.2022.100170
17. Charlton A, Vidal X, Sabaté M, et al. Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation. J Manag Care Specy Pharm. 2021;27(9):1210-20. DOI:10.18553/jmcp.2021.27.9.1210
18. Bartolazzi F, Ribeiro A, de Sousa W, et al. Relationship of health literacy and adherence to oral anticoagulation therapy in patients with atrial fibrillation: a cross-sectional study. J Thromb Thrombolysis. 2021;52(4):1074-80. DOI:10.1007/s11239-021-02432-4
19. Ferguson C, Inglis S, Newton P, et al. Barriers and enablers to adherence to anticoagulation in heart failure with atrial fibrillation: patient and provider perspectives. J Clin Nurs. 2017;26(23-24):4325-34. DOI:10.1111/jocn.13759
20. Cabellos-Garcia A, Martinez-Sabater A, Castro-Sanchez E, et al. Relation between health literacy, self-care and adherence to treatment with oral anticoagulants in adults: a narrative systematic review. BMC Public Health. 2018;18(1):1-12. DOI:10.1186/s12889-018-6070-9
21. Lemstra M, Nwankwo C, Bird Y, Moraros J. Primary nonadherence to chronic disease medications: a meta-analysis. Patient Prefer Adherence. 2018;12:721. DOI:10.2147/PPA.S161151
22. Mandalenakis Z, Von Koch L, Eriksson H, et al. The risk of atrial fibrillation in the general male population: a lifetime follow-up of 50-year-old men. Europace. 2015;17(7):1018-22. DOI:10.1093/europace/euv036
23. Friberg L, Rosenqvist M, Lip G. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-10. DOI:10.1093/eurheartj/ehr488
24. LaMori J, Mody S, Gross H, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53-62. DOI:10.1177/17539447124641
25. Деменко Т.Н., Чумакова Г.А., Чугунова Ю.В. Особенности когнитивной функции у пациентов с фибрилляцией предсердий. Анналы аритмологии. 2015;12(4):215-24 [Demenko TN, Chumakova GA, Chugunova YV. Features of cognitive function in patients with atrial fibrillation. Annaly aritmologii. 2015;12(4):215-24 (in Russian)]. DOI:10.15275/annaritmol.2015.4.3
26. Rohde D, Merriman N, Doyle F, et al. Does cognitive impairment impact adherence? A systematic review and meta-analysis of the association between cognitive impairment and medication non-adherence in stroke. PloS One. 2017;12(12):e0189339. DOI:10.1371/journal.pone.0189339
27. Кобалава Ж.Д., Лазарев П.В., Федорова Д.Н. Когнитивная дисфункция на фоне фибрилляции предсердий: клинико-патогенетические ассоциации, диагностика и профилактика, аспекты применения антикоагулянтной терапии. Кардиология. 2019;59(10):66-77 [Kobalava ZD, Lazarev PV, Fedorova DN. Cognitive Dysfunction at the Background of Atrial Fibrillation: Clinical-Pathological Aspects, Diagnostics and Prevention, Issues of the Use of the Application of Anticoagulant Therapy. Kardiologiia. 2019;59(10):66-77 (in Russian)]. DOI:10.18087/cardio.2019.10.n612
28. Gallagher A, Rietbrock S, Plumb J, Van Staa T. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemostas. 2008;6(9):1500-6. DOI:10.1111/j.1538-7836.2008.03059.x
29. Castellucci L, Shaw J, van der Salm K, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thrombosis Res. 2015;136(4):727-31. DOI:10.1016/j.thromres.2015.07.007
30. Emren S, Şenöz O, Bilgin M, et al. Drug adherence in patients with nonvalvular atrial fibrillation taking non-vitamin K antagonist oral anticoagulants in Turkey: NOAC-TR. Clin Appl Thromb Hemost. 2018;24(3):525-31. DOI:10.1177/1076029617693940
31. Zielinski G, van Rein N, Teichert M, et al. Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: a surveillance study. Res Pract Thromb Haemost. 2020;4(1):141-53. DOI:10.1002/rth2.12261
32. Smith D, Lovell J, Weller C, et al. A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PloS One. 2017;12(2):e0170651. DOI:10.1371/journal.pone.0170651
33. Patel D, McConkey N, Sohaney R, et al. A systematic review of depression and anxiety in patients with atrial fibrillation: the mind-heart link. Cardiovasc Psychiatry Neurol. 2013;2013:159850. DOI:10.1155/2013/159850
34. Polikandrioti M, Koutelekos I, Vasilopoulos G, et al. Anxiety and depression in patients with permanent atrial fibrillation: prevalence and associated factors. Cardiol Res Pract. 2018;2018:7408129. DOI:10.1155/2018/7408129
35. Søgaard M, Skjøth F, Kjældgaard J, et al. Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study. BMJ Open. 2017;7(12):e018209. DOI:10.1136/bmjopen-2017-018209
36. Wu M, Shen L, Wang Q, et al. Anxiety and Depression Prevalence and Risk Factors Among Patients With Cardiovascular Diseases in Post-COVID-19 China. Front Public Health. 2022;9:758874. DOI:10.3389/fpubh.2021.758874
37. Walker E, McGee R, Druss B. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334-41. DOI:10.1001/jamapsychiatry.2014.2502
38. Jayatilleke N, Hayes R, Dutta R, et al. Contributions of specific causes of death to lost life expectancy in severe mental illness. Eur Psychiatry. 2017;43:109-15. DOI:10.1016/j.eurpsy.2017.02.487
39. McGrady A, McGinnis R, Badenhop D, et al. Effects of depression and anxiety on adherence to cardiac rehabilitation. J Cardiopulm Rehabil Prevn. 2009;29(6):358-64. DOI:10.1097/HCR.0b013e3181be7a8f
40. Fenger-Grøn M, Vestergaard C, Frost L, et al. Depression and uptake of oral anticoagulation therapy in patients with atrial fibrillation: a Danish nationwide cohort study. Medical Care. 2020;58(3):216-24. DOI:10.1097/MLR.0000000000001268
41. Reading S, Black M, Singer D, et al. Risk factors for medication non-adherence among atrial fibrillation patients. BMC Cardiovasc Disord. 2019;19(1):38.
DOI:10.1186/s12872-019-1019-1
42. Bauer LK, Caro MA, Beach SR, et al. Effects of depression and anxiety improvement on adherence to medication and health behaviors in recently hospitalized cardiac patients. Am J Cardiol. 2012;109(9):1266-71. DOI:10.1016/j.amjcard.2011.12.017
43. Suzuki T, Shiga T, Omori H, et al. Adherence to medication and characteristics of Japanese patients with non-valvular atrial fibrillation. J Cardiol. 2017;70(3):238-43. DOI:10.1016/j.jjcc.2016.11.009
44. Taylor E, O'Neill M, Hughes L, et al. Examining adherence to medication in patients with atrial fibrillation: the role of medication beliefs, attitudes, and depression. J Cardiovasc Nurs. 2020;35(4):337-46. DOI:10.1097/JCN.0000000000000650
45. Teppo K, Jaakkola J, Airaksinen K, et al. Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study. J Am Heart Assoc. 2022;11(6):e024119. DOI:10.1161/JAHA.121.024119
46. Miyazaki M, Nakashima A, Nakamura Y, et al. Association between medication adherence and illness perceptions in atrial fibrillation patients treated with direct oral anticoagulants: an observational cross-sectional pilot study. PloS One. 2018;13(9):e0204814. DOI:10.1371/journal.pone.0204814
47. Lane D, Meyerhoff J, Rohner U, Lip G. Patients’ perceptions of atrial fibrillation, stroke risk, and oral anticoagulation treatment: An international survey. TH Open. 2018;2(03):e233-41. DOI:10.1055/s-0038-1666803
48. Алёхин А.Н., Трифонова Е.А., Лебедев Д.С., и др. Психологические проблемы в аритмологии (на модели фибрилляции предсердий). Вестник аритмологии. 2011;63:45-54 [Alekhin AN, Trifonova EA, Lebedev DS, et al. Psuchological problems in arrhythmology (on a model of atrial fibrillation). Vestnik aritmologii. 2011;63:45-54 (in Russian)].
49. Streur M, Ratcliffe SJ, Callans D, et al. Atrial fibrillation symptom clusters and associated clinical characteristics and outcomes: A cross-sectional secondary data analysis. Eur J Cardiovasc Nurs. 2018;17(8):707-16. DOI:10.1177/1474515118778445
________________________________________________
1. Chugh S, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47. DOI:10.1161/CIRCULATIONAHA.113.005119
2. Dai H, Zhang Q, Much A, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):574-82. DOI:10.1093/ehjqcco/qcaa061
3. Mareev YuV, Polyakov DS, Vinogradova NG, et al. Epidemiology of atrial fibrillation in a representative sample of the European part of the Russian Federation. Analysis of EPOCH-CHF Study. Kardiologiia. 2022;62(4):12-9 (in Russian). DOI:10.18087/cardio.2022.4.n1997
4. Belenkov YuN, Shakaryants GA, Khabarova NV, An GV. Anticoagulant Therapy in Elderly Patients With Atrial Fibrillation. Kardiologiia. 2018;58(10):45-52 (in Russian). DOI:10.18087/cardio.2018.10.10177
5. Bockeria LA, Polunina AG, Lefterova NF, et al. Atrium fibrillation and enlargement of left heart chambers: pathological mechanisms of cognitive dysfunction in cardiologic patients. Creative Cardiology. 2015;9(1):38-45 (in Russian). DOI:10.15275/kreatkard.2015.01.04
6. Diagnostika i lechenie fibrilliatsii predserdii. Klinicheskie rekomendatsii, 2017. Available at: https://racvs.ru/clinic/files/2017/Atrial-Fibrillation.pdf. Accessed: 26.09.2022 (in Russian).
7. Salmasi S, Loewen P, Tandun R, et al. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. BMJ Open. 2020;10(4):e034778. DOI:10.1136/bmjopen-2019-034778
8. Jankowska-Polańska B, Lomper K, Alberska L, et al. Cognitive function and adherence to anticoagulation treatment in patients with atrial fibrillation. J Geriatr Cardiol. 2016;13(7):559. DOI:10.11909/j.issn.1671-5411.2016.07.006
9. Obamiro K, Chalmers L, Lee K, et al. Adherence to oral anticoagulants in atrial fibrillation: An Australian survey. Cardiovasc Pharm Ther. 2018;23:337-43. DOI:10.1177/1074248418770201
10. Seong H, Lee K, Kim B, Son Y. Cognitive impairment is independently associated with non-adherence to antithrombotic therapy in older patients with atrial fibrillation. Int J Environ Res Public Health. 2019;16(15):2698. DOI:10.3390/ijerph16152698
11. Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Thromb Haemost. 2017;117(02):209-18.
DOI:10.1160/TH16-10-0757
12. Cramer J, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7. DOI:10.1111/j.1524-4733.2007.00213.x
13. Tomasdottir M, Friberg L, Hijazi Z, et al. Risk of ischemic stroke and utility of CHA2DS2-VASc score in women and men with atrial fibrillation. Clin Cardiol. 2019;42(10):1003-9. DOI:10.1002/clc.23257
14. Lip G, Laroche C, Popescu M, et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. EP Europace. 2015;17(12):1777-86. DOI:10.1093/europace/euv269
15. Thompson L, Maddox T, Lei L, et al. Sex differences in the use of oral anticoagulants for atrial fibrillation: a report from the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry. J Am Heart Assoc. 2017;6(7):e005801. DOI:10.1161/JAHA.117.005801
16. Eckman M, Wise R, Leonard A, et al. Racial and sex differences in optimizing anticoagulation therapy for patients with atrial fibrillation. American Heart Journal Plus: Cardiology Research and Practice. 2022;18:100170. DOI:10.1016/j.ahjo.2022.100170
17. Charlton A, Vidal X, Sabaté M, et al. Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation. J Manag Care Specy Pharm. 2021;27(9):1210-20. DOI:10.18553/jmcp.2021.27.9.1210
18. Bartolazzi F, Ribeiro A, de Sousa W, et al. Relationship of health literacy and adherence to oral anticoagulation therapy in patients with atrial fibrillation: a cross-sectional study. J Thromb Thrombolysis. 2021;52(4):1074-80. DOI:10.1007/s11239-021-02432-4
19. Ferguson C, Inglis S, Newton P, et al. Barriers and enablers to adherence to anticoagulation in heart failure with atrial fibrillation: patient and provider perspectives. J Clin Nurs. 2017;26(23-24):4325-34. DOI:10.1111/jocn.13759
20. Cabellos-Garcia A, Martinez-Sabater A, Castro-Sanchez E, et al. Relation between health literacy, self-care and adherence to treatment with oral anticoagulants in adults: a narrative systematic review. BMC Public Health. 2018;18(1):1-12. DOI:10.1186/s12889-018-6070-9
21. Lemstra M, Nwankwo C, Bird Y, Moraros J. Primary nonadherence to chronic disease medications: a meta-analysis. Patient Prefer Adherence. 2018;12:721. DOI:10.2147/PPA.S161151
22. Mandalenakis Z, Von Koch L, Eriksson H, et al. The risk of atrial fibrillation in the general male population: a lifetime follow-up of 50-year-old men. Europace. 2015;17(7):1018-22. DOI:10.1093/europace/euv036
23. Friberg L, Rosenqvist M, Lip G. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-10. DOI:10.1093/eurheartj/ehr488
24. LaMori J, Mody S, Gross H, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53-62. DOI:10.1177/17539447124641
25. Деменко Т.Н., Чумакова Г.А., Чугунова Ю.В. Особенности когнитивной функции у пациентов с фибрилляцией предсердий. Анналы аритмологии. 2015;12(4):215-24 [Demenko TN, Chumakova GA, Chugunova YV. Features of cognitive function in patients with atrial fibrillation. Annaly aritmologii. 2015;12(4):215-24 (in Russian)]. DOI:10.15275/annaritmol.2015.4.3
26. Rohde D, Merriman N, Doyle F, et al. Does cognitive impairment impact adherence? A systematic review and meta-analysis of the association between cognitive impairment and medication non-adherence in stroke. PloS One. 2017;12(12):e0189339. DOI:10.1371/journal.pone.0189339
27. Kobalava ZD, Lazarev PV, Fedorova DN. Cognitive Dysfunction at the Background of Atrial Fibrillation: Clinical-Pathological Aspects, Diagnostics and Prevention, Issues of the Use of the Application of Anticoagulant Therapy. Kardiologiia. 2019;59(10):66-77 (in Russian). DOI:10.18087/cardio.2019.10.n612
28. Gallagher A, Rietbrock S, Plumb J, Van Staa T. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemostas. 2008;6(9):1500-6. DOI:10.1111/j.1538-7836.2008.03059.x
29. Castellucci L, Shaw J, van der Salm K, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thrombosis Res. 2015;136(4):727-31. DOI:10.1016/j.thromres.2015.07.007
30. Emren S, Şenöz O, Bilgin M, et al. Drug adherence in patients with nonvalvular atrial fibrillation taking non-vitamin K antagonist oral anticoagulants in Turkey: NOAC-TR. Clin Appl Thromb Hemost. 2018;24(3):525-31. DOI:10.1177/1076029617693940
31. Zielinski G, van Rein N, Teichert M, et al. Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: a surveillance study. Res Pract Thromb Haemost. 2020;4(1):141-53. DOI:10.1002/rth2.12261
32. Smith D, Lovell J, Weller C, et al. A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PloS One. 2017;12(2):e0170651. DOI:10.1371/journal.pone.0170651
33. Patel D, McConkey N, Sohaney R, et al. A systematic review of depression and anxiety in patients with atrial fibrillation: the mind-heart link. Cardiovasc Psychiatry Neurol. 2013;2013:159850. DOI:10.1155/2013/159850
34. Polikandrioti M, Koutelekos I, Vasilopoulos G, et al. Anxiety and depression in patients with permanent atrial fibrillation: prevalence and associated factors. Cardiol Res Pract. 2018;2018:7408129. DOI:10.1155/2018/7408129
35. Søgaard M, Skjøth F, Kjældgaard J, et al. Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study. BMJ Open. 2017;7(12):e018209. DOI:10.1136/bmjopen-2017-018209
36. Wu M, Shen L, Wang Q, et al. Anxiety and Depression Prevalence and Risk Factors Among Patients With Cardiovascular Diseases in Post-COVID-19 China. Front Public Health. 2022;9:758874. DOI:10.3389/fpubh.2021.758874
37. Walker E, McGee R, Druss B. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334-41. DOI:10.1001/jamapsychiatry.2014.2502
38. Jayatilleke N, Hayes R, Dutta R, et al. Contributions of specific causes of death to lost life expectancy in severe mental illness. Eur Psychiatry. 2017;43:109-15. DOI:10.1016/j.eurpsy.2017.02.487
39. McGrady A, McGinnis R, Badenhop D, et al. Effects of depression and anxiety on adherence to cardiac rehabilitation. J Cardiopulm Rehabil Prevn. 2009;29(6):358-64. DOI:10.1097/HCR.0b013e3181be7a8f
40. Fenger-Grøn M, Vestergaard C, Frost L, et al. Depression and uptake of oral anticoagulation therapy in patients with atrial fibrillation: a Danish nationwide cohort study. Medical Care. 2020;58(3):216-24. DOI:10.1097/MLR.0000000000001268
41. Reading S, Black M, Singer D, et al. Risk factors for medication non-adherence among atrial fibrillation patients. BMC Cardiovasc Disord. 2019;19(1):38.
DOI:10.1186/s12872-019-1019-1
42. Bauer LK, Caro MA, Beach SR, et al. Effects of depression and anxiety improvement on adherence to medication and health behaviors in recently hospitalized cardiac patients. Am J Cardiol. 2012;109(9):1266-71. DOI:10.1016/j.amjcard.2011.12.017
43. Suzuki T, Shiga T, Omori H, et al. Adherence to medication and characteristics of Japanese patients with non-valvular atrial fibrillation. J Cardiol. 2017;70(3):238-43. DOI:10.1016/j.jjcc.2016.11.009
44. Taylor E, O'Neill M, Hughes L, et al. Examining adherence to medication in patients with atrial fibrillation: the role of medication beliefs, attitudes, and depression. J Cardiovasc Nurs. 2020;35(4):337-46. DOI:10.1097/JCN.0000000000000650
45. Teppo K, Jaakkola J, Airaksinen K, et al. Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study. J Am Heart Assoc. 2022;11(6):e024119. DOI:10.1161/JAHA.121.024119
46. Miyazaki M, Nakashima A, Nakamura Y, et al. Association between medication adherence and illness perceptions in atrial fibrillation patients treated with direct oral anticoagulants: an observational cross-sectional pilot study. PloS One. 2018;13(9):e0204814. DOI:10.1371/journal.pone.0204814
47. Lane D, Meyerhoff J, Rohner U, Lip G. Patients’ perceptions of atrial fibrillation, stroke risk, and oral anticoagulation treatment: An international survey. TH Open. 2018;2(03):e233-41. DOI:10.1055/s-0038-1666803
48. Alekhin AN, Trifonova EA, Lebedev DS, et al. Psuchological problems in arrhythmology (on a model of atrial fibrillation). Vestnik aritmologii. 2011;63:45-54 (in Russian).
49. Streur M, Ratcliffe SJ, Callans D, et al. Atrial fibrillation symptom clusters and associated clinical characteristics and outcomes: A cross-sectional secondary data analysis. Eur J Cardiovasc Nurs. 2018;17(8):707-16. DOI:10.1177/1474515118778445
Авторы
Д.В. Трошина*1, Д.А. Андреев1, А.В. Фомичева1, А.Н. Воловченко1, Б.А. Волель1,2
1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБНУ «Научный центр психического здоровья», Москва, Россия
*troshina_d_v@staff.sechenov.ru
1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБНУ «Научный центр психического здоровья», Москва, Россия
*troshina_d_v@staff.sechenov.ru
________________________________________________
Daria V. Troshina*1, Denis A. Andreev1, Anastasia V. Fomicheva1, Alexey N. Volovchenko1, Beatrice A. Volel1,2
1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2 Mental Health Research Center, Moscow, Russia
*troshina_d_v@staff.sechenov.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.